ArticleEClinicalMedicine2024
Intrapartum antibiotic prophylaxis to prevent Group B streptococcal infections in newborn infants: a systematic review and meta-analysis comparing various strategies.
Article in EClinicalMedicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Systematic Review and Meta-analysis of Group B Streptococcus Rectovaginal Colonization Rates and Serotype Distribution among Pregnant Women, Asia-Pacific Region, 2014-2025.Emerging infectious diseases · 2026Pooled it
- Intrapartum Antibiotic Prophylaxis and Child Health Outcomes: A Systematic Review and Meta-Analysis of Observational Studies.BJOG : an international journal of obstetrics and gynaecology · 2026Pooled it
- Maternal 6-valent group B Streptococcus vaccine in non-pregnant and pregnant females: a randomized phase 1/2 trial.Nature medicine · 2026Trial
- A Phase 2b Trial Evaluating the Safety, Tolerability, and Immunogenicity of a 6-Valent Group B Streptococcus Vaccine Administered Concomitantly With Tetanus, Diphtheria, and Acellular Pertussis Vaccine in Healthy Nonpregnant Female Individuals.The Journal of infectious diseases · 2025Trial
- Time to rethink prevention of neonatal group B streptococcal disease.Seminars in immunopathology · 2026Review
- Gestational age modifies associations between Group B Streptococcus genomic characteristics and postnatal age at disease onset.Nature communications · 2026Article
- Trends in the annual incidence and risk factors of cerebral palsy.Pediatric research · 2026Article
- Benefits and Harms of Antenatal/Intrapartum Screening for Maternal Group B Streptococcus and Use of Intrapartum Antibiotic Prophylaxis Versus Risk-Based Protocols or No Intervention: A Rapid Review.Acta paediatrica (Oslo, Norway : 1992) · 2026Review
- The Maternal Microbiome in Pregnancy: From Physiological Changes to Dysbiosis and Obstetrical Complications-Therapeutic Perspectives.Life (Basel, Switzerland) · 2026Review
- Group B Streptococcus antibiotics treatment during pregnancy and the risk of four neurodevelopmental outcomes in Swedish children.Scientific reports · 2026Article
- Mother-to-offspring microbial vertical transmission: timing, determinants, and impact on offspring susceptibility to gastrointestinal diseases.Medical review (2021) · 2026Review
- Facing Antimicrobial Resistance and Virulence in Streptococcus agalactiae During Late Pregnancy: Evaluation of Lactobacilli as a Supportive Approach.MicrobiologyOpen · 2026Article
- Metagenomic survey of pathogen prevalence in the infant gut.Scientific reports · 2026Article
- Association of Chorioamnionitis with Early and Late Neonatal Sepsis in Preterm Infants with Gestational Age < 32 Weeks.Diagnostics (Basel, Switzerland) · 2026Article
- Antibiotic Prophylaxis and Treatment of Neonatal Group B Streptococcus Disease in the Era of Antimicrobial Resistance.Antibiotics (Basel, Switzerland) · 2026Review
- Current knowledge and future perspectives on management and prevention of group B streptococcus in neonates and young infants.Archives of disease in childhood. Fetal and neonatal edition · 2026Review
- Prevalence of Candidate Vaccine Targets and Genomic Features of Pediatric Invasive Streptococcus Agalactiae in Japan.The Journal of infectious diseases · 2026Article
- Whole-genome characterization of neonatal group B Streptococcus infection isolates and contemporaneous maternal colonizing isolates in Southwest China.Frontiers in microbiology · 2026Article
- Adaptive microevolution in CC17Frontiers in cellular and infection microbiology · 2026Article
- Pharmacokinetics of Intrapartum Benzylpenicillin: Insights Into Candidate Regimens to Prevent Early Onset Neonatal Group B Streptococcus Disease.CPT: pharmacometrics & systems pharmacology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Background: Early-onset Group B Streptococcus (EOGBS) infection leads to substantial morbidity and mortality in newborn infants. Intrapartum antibiotic prophylaxis (IAP) prevents EOGBS infection, but IAP strategies vary. The approach to the provision of IAP can be risk-based, universal or a combination of the two strategies. Previous systematic reviews reported that universal strategies might be most optimal in lowering EOGBS infection, but there is no consensus. Therefore, we aimed to provide up-to-date evidence on effectiveness of different strategies by comparing perinatal outcomes. Methods: A systematic search for EOGBS prevention strategies was performed in MEDLINE, Embase and Web of Science on May 2024. Studies were included if they reported on different strategies and outcomes of interest, including EOGBS infection, IAP administration and antimicrobial resistance regardless of publication date. Summary data was extracted from published reports. Study quality was assessed using the ROBINS-I tool. Random-effects meta-analyses were used to determine risk ratios (RR) and 95%-confidence intervals. PROSPERO registration CRD42023411806. Findings: A total of 6293 records were identified, of which 72 observational studies were included for synthesis with more than 10 million live births. Meta-analysis demonstrated that implementation of any strategy (n = 34 studies, RR 0.46 (0.36-0.60)), risk-based strategies (n = 11 studies, RR 0.65 (0.48-0.87)), or universal strategies (n = 16 studies, RR 0.37 (0.25-0.55)) was associated with a reduced risk of EOGBS infection compared to no strategy. In direct comparison, universal strategies were associated with a reduced risk of EOGBS compared to a risk-based strategy (n = 17 studies, RR 0.41 (0.30-0.55)), while the proportion of women receiving IAP did not differ between risk-based (16%) and universal (21%) strategies (n = 9 studies, RR 1.29 (0.95-1.75)). There was no antimicrobial resistance of EOGBS isolates to penicillin or ampicillin (n = 11 studies). Interpretation: Any IAP strategy could reduce the risk of EOGBS infection without evidence of increasing antimicrobial resistance. Universal strategies give the largest reduction in the EOGBS burden, while not exposing a significantly higher proportion of pregnancies to IAP compared to risk-based strategies. Funding: UNDP-UNFPA-UNICEF-WHO-World Bank Special Programme of Research, Development and Research Training in Human Reproduction, a cosponsored programme executed by the World Health Organization.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.